---
content_type: page
description: This section provides information on the course textbooks and the schedule
  of readings by lecture session and topic.
learning_resource_types:
- Readings
ocw_type: CourseSection
title: Readings
uid: 929a5c8f-c944-484a-681d-448e0140ed3b
---

\[Golan\] = Golan, David E., Armen H. Tashjian, and Ehrin J. Armstrong, eds. _Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy_. Lippincott Williams & Wilkins, 2011. ISBN: 9781608312702. \[Preview with [Google Books](http://books.google.com/books?id=WM7rvNUcrdsC&pg=PAfrontcover)\]

\[C&D\] = Klaassen, Curtis. _Casarett & Doull's Toxicology: The Basic Science of Poisons_. 8th ed. McGraw-Hill Professional, 2013. ISBN: 9780071769235.

{{< tableopen >}}
{{< theadopen >}}
{{< tropen >}}
{{< thopen >}}
SES #
{{< thclose >}}
{{< thopen >}}
TOPICS
{{< thclose >}}
{{< thopen >}}
READINGS
{{< thclose >}}

{{< trclose >}}

{{< theadclose >}}
{{< tropen >}}
{{< tdopen colspan="4" >}}
**Overview of the Drug Discovery Process; Fundamental Principles**
{{< tdclose >}}

{{< trclose >}}
{{< tropen >}}
{{< tdopen >}}
L1
{{< tdclose >}}
{{< tdopen >}}
Introduction and Fundamentals
{{< tdclose >}}
{{< tdopen >}}
\[Golan\] Chapter 1
{{< tdclose >}}

{{< trclose >}}
{{< tropen >}}
{{< tdopen >}}
L2
{{< tdclose >}}
{{< tdopen >}}
Overview of Drug Development 1
{{< tdclose >}}
{{< tdopen >}}
\[Golan\] Chapter 49
{{< tdclose >}}

{{< trclose >}}
{{< tropen >}}
{{< tdopen >}}
L3
{{< tdclose >}}
{{< tdopen >}}
Overview of Drug Development 2
{{< tdclose >}}
{{< tdopen >}}
\[Golan\] Chapter 49
{{< tdclose >}}

{{< trclose >}}
{{< tropen >}}
{{< tdopen >}}
R1
{{< tdclose >}}
{{< tdopen >}}
Fundamentals
{{< tdclose >}}
{{< tdopen >}}
\[Golan\] Chapters 1 and 2
{{< tdclose >}}

{{< trclose >}}
{{< tropen >}}
{{< tdopen >}}
L4
{{< tdclose >}}
{{< tdopen >}}
Biochemistry Review Exercise
{{< tdclose >}}
{{< tdopen >}}
No readings for this session.
{{< tdclose >}}

{{< trclose >}}
{{< tropen >}}
{{< tdopen >}}
L5
{{< tdclose >}}
{{< tdopen >}}
Uptake and Distribution
{{< tdclose >}}
{{< tdopen >}}


\[Golan\] Chapters 2 and 3

\[C&D\] Chapter 5


{{< tdclose >}}

{{< trclose >}}
{{< tropen >}}
{{< tdopen >}}
L6
{{< tdclose >}}
{{< tdopen >}}
Dr. Keith Hoffmaster, Novartis: Drug Transporters 1
{{< tdclose >}}
{{< tdopen >}}


\[Golan\] Chapter 4

\[C&D\] Chapter 7

Giacomini, Kathleen M., Shiew-Mei Huang, et al. "[Membrane Transporters in Drug Development](http://dx.doi.org/10.1038/nrd3028)." _Nature Reviews Drug Discovery_ 9, no. 3 (2010): 215–36.

Brouwer, Kim L. R., Dietrich Keppler, et al. "[In Vitro Methods to Support Transporter Evaluation in Drug Discovery and Development.](http://www.zora.uzh.ch/93549/1/clpt201381a.pdf)" _Clinical Pharmacology & Therapeutics_ 94, no. 1 (2013): 95–112.


{{< tdclose >}}

{{< trclose >}}
{{< tropen >}}
{{< tdopen >}}
L7
{{< tdclose >}}
{{< tdopen >}}
Dr. Keith Hoffmaster, Novartis: Drug Transporters 2
{{< tdclose >}}
{{< tdopen >}}


\[Golan\] Chapter 4

\[C&D\] Chapter 7


{{< tdclose >}}

{{< trclose >}}
{{< tropen >}}
{{< tdopen >}}
R2
{{< tdclose >}}
{{< tdopen >}}
Drug Metabolism 1
{{< tdclose >}}
{{< tdopen >}}


\[Golan\] Chapter 4


{{< tdclose >}}

{{< trclose >}}
{{< tropen >}}
{{< tdopen >}}
L8
{{< tdclose >}}
{{< tdopen >}}
Drug Metabolism 2
{{< tdclose >}}
{{< tdopen >}}


\[Golan\] Chapter 4


{{< tdclose >}}

{{< trclose >}}
{{< tropen >}}
{{< tdopen >}}
L9
{{< tdclose >}}
{{< tdopen >}}
Drug Toxicity 1
{{< tdclose >}}
{{< tdopen >}}


\[Golan\] Chapters 5 and 41

[_Guidance for Industry: Drug-Induced Liver Injury: Premarketing Clinical Evaluation_. (PDF)](https://www.fda.gov/media/116737/download) U.S. Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER). July 2009.

Giacomini, Kathleen M., Shiew-Mei Huang, et al. "[Membrane Transporters in Drug Development](http://dx.doi.org/10.1038/nrd3028)." _Nature Reviews Drug Discovery_ 9, no. 3 (2010): 215–36.


{{< tdclose >}}

{{< trclose >}}
{{< tropen >}}
{{< tdopen >}}
R3
{{< tdclose >}}
{{< tdopen >}}
Lecture Review Session
{{< tdclose >}}
{{< tdopen >}}
No readings for this session.
{{< tdclose >}}

{{< trclose >}}
{{< tropen >}}
{{< tdopen >}}
L10
{{< tdclose >}}
{{< tdopen >}}
Drug Toxicity 2
{{< tdclose >}}
{{< tdopen >}}


\[Golan\] Chapters 5 and 41


{{< tdclose >}}

{{< trclose >}}
{{< tropen >}}
{{< tdopen >}}
L11
{{< tdclose >}}
{{< tdopen >}}
Pharmacokinetics
{{< tdclose >}}
{{< tdopen >}}


\[Golan\] Chapters 2 and 3

\[C&D\] Chapter 5


{{< tdclose >}}

{{< trclose >}}
{{< tropen >}}
{{< tdopen >}}
R4
{{< tdclose >}}
{{< tdopen >}}
Quiz Review
{{< tdclose >}}
{{< tdopen >}}
No readings for this session.
{{< tdclose >}}

{{< trclose >}}
{{< tropen >}}
{{< tdopen colspan="4" >}}
**Case Studies and Literature Discussions; Case Study Project**
{{< tdclose >}}

{{< trclose >}}
{{< tropen >}}
{{< tdopen >}}
L12
{{< tdclose >}}
{{< tdopen >}}
Case Study: Omeprazole Pharmacogenetics
{{< tdclose >}}
{{< tdopen >}}


Chang, M., G. Tybring, et al. "[Interphenotype Differences in Disposition and Effect on Gastrin Levels of Omeprazole—Suitability of Omeprazole as a Probe for CYP2C19](http://dx.doi.org/10.1111/j.1365-2125.1995.tb04488.x)." _British Journal of Clinical Pharmacology_ 39, no. 5 (1995): 511–18.

Furuta, Takahisa, Mitsushige Sugimoto, et al. "[CYP2C19 Pharmacogenomics Associated with Therapy of Helicobacter Pylori Infection and Gastro-Esophageal Reflux Diseases with a pPoton Pump Inhibitor](http://dx.doi.org/10.2217/14622416.8.9.1199)." _Pharmacogenomics_ 8, no. 9 (2007): 1199–210.

Lindberg, Per, Peter Nordberg, et al. "[The Mechanism of Action of the Antisecretory Agent Omeprazole](http://dx.doi.org/10.1021/jm00158a001)." _Journal of Medicinal Chemistry_ 29, no. 8 (1986): 1327–29.

Court, Michael H. "[A Pharmacogenomics Primer](http://dx.doi.org/10.1177/0091270007303768)." _The Journal of Clinical Pharmacology_ 47, no. 9 (2007): 1087–103.

\[Golan\] Chapter 6 and 46


{{< tdclose >}}

{{< trclose >}}
{{< tropen >}}
{{< tdopen >}}
R5
{{< tdclose >}}
{{< tdopen >}}
Overview of Drug Development 3
{{< tdclose >}}
{{< tdopen >}}
\[Golan\] Chapter 49
{{< tdclose >}}

{{< trclose >}}
{{< tropen >}}
{{< tdopen >}}
L13
{{< tdclose >}}
{{< tdopen >}}
Case Study
{{< tdclose >}}
{{< tdopen >}}
No readings for this session.
{{< tdclose >}}

{{< trclose >}}
{{< tropen >}}
{{< tdopen >}}
L14
{{< tdclose >}}
{{< tdopen >}}
Case Study: Antibiotics
{{< tdclose >}}
{{< tdopen >}}


\[Golan\] Chapters 32, 33, and 34

[Antibiotic Resistance Threats in the United States, 2013](http://www.cdc.gov/drugresistance/threat-report-2013/) {{% resource_link 13e2b479-19d3-fe1b-1da0-e7eeb27b6e4d "(PDF - 4.0MB)" %}} Centers for Disease Control and Prevention.

Dwyer, Daniel J., Michael A. Kohanski, et al. "[Role of Reactive Oxygen Species in Antibiotic Action and Resistance](http://dx.doi.org/10.1016/j.mib.2009.06.018)." _Current Opinion in Microbiology_ 12, no. 5 (2009): 482–9.


{{< tdclose >}}

{{< trclose >}}
{{< tropen >}}
{{< tdopen >}}
R6
{{< tdclose >}}
{{< tdopen >}}
Project Help Session
{{< tdclose >}}
{{< tdopen >}}
No readings for this session.
{{< tdclose >}}

{{< trclose >}}
{{< tropen >}}
{{< tdopen >}}
L15
{{< tdclose >}}
{{< tdopen >}}
Case Study
{{< tdclose >}}
{{< tdopen >}}
No readings for this session.
{{< tdclose >}}

{{< trclose >}}
{{< tropen >}}
{{< tdopen >}}
L16
{{< tdclose >}}
{{< tdopen >}}
Dr. Alex Wood, MIT Senior Lecturer/Novartis: Case Study: Oncology Drugs
{{< tdclose >}}
{{< tdopen >}}
Hanahan, Douglas, and Robert A. Weinberg. "[Hallmarks of Cancer: The Next Generation](http://dx.doi.org/10.1016/j.cell.2011.02.013)." _Cell_ 144, no. 5 (2011): 646–74.
{{< tdclose >}}

{{< trclose >}}
{{< tropen >}}
{{< tdopen >}}
R7
{{< tdclose >}}
{{< tdopen >}}
Project Help Session
{{< tdclose >}}
{{< tdopen >}}
No readings for this session.
{{< tdclose >}}

{{< trclose >}}
{{< tropen >}}
{{< tdopen >}}
L17
{{< tdclose >}}
{{< tdopen >}}
Case Study: Statins
{{< tdclose >}}
{{< tdopen >}}


\[Golan\] Chapter 19

Press Release: "[Rate of Kidney Damage in Crestor Patients Is 75 Times Higher Than in Patients Taking Other Cholesterol Drugs](http://www.citizen.org/pressroom/pressroomredirect.cfm?ID=1819)." October 29, 2004.


{{< tdclose >}}

{{< trclose >}}
{{< tropen >}}
{{< tdopen >}}
R8
{{< tdclose >}}
{{< tdopen >}}
Project Help Session
{{< tdclose >}}
{{< tdopen >}}
No readings for this session.
{{< tdclose >}}

{{< trclose >}}
{{< tropen >}}
{{< tdopen >}}
L18
{{< tdclose >}}
{{< tdopen >}}
Case Study: GWAS and Statin Toxicity
{{< tdclose >}}
{{< tdopen >}}


Niemi, M. "[Transporter Pharmacogenetics and Statin Toxicity](http://dx.doi.org/10.1038/clpt.2009.197)." _Clinical Pharmacology & Therapeutics_ 87, no. 1 (2010): 130–3.

Link, E., S. Parish, et al. "[SLCO1B1 Variants and Statin-Induced Myopathy—A Genomewide Study](http://dx.doi.org/10.1056/NEJMoa0801936)." _The New England Journal of Medicine_ 359, no. 8 (2008): 789.


{{< tdclose >}}

{{< trclose >}}
{{< tropen >}}
{{< tdopen >}}
L19
{{< tdclose >}}
{{< tdopen >}}
Dr. Bernard Fermini, Pfizer: Case Study: Cardiotoxicity
{{< tdclose >}}
{{< tdopen >}}
No readings for this session.
{{< tdclose >}}

{{< trclose >}}
{{< tropen >}}
{{< tdopen >}}
R9
{{< tdclose >}}
{{< tdopen >}}
Project Help Session
{{< tdclose >}}
{{< tdopen >}}
No readings for this session.
{{< tdclose >}}

{{< trclose >}}
{{< tropen >}}
{{< tdopen >}}
L20
{{< tdclose >}}
{{< tdopen >}}
Dr. Teresa Wright, Shire Pharmaceuticals: Preclinical Drug Development
{{< tdclose >}}
{{< tdopen >}}
\[Golan\] Chapter 49
{{< tdclose >}}

{{< trclose >}}
{{< tropen >}}
{{< tdopen >}}
R10
{{< tdclose >}}
{{< tdopen >}}
Project Help Session
{{< tdclose >}}
{{< tdopen >}}
No readings for this session.
{{< tdclose >}}

{{< trclose >}}
{{< tropen >}}
{{< tdopen >}}
L21
{{< tdclose >}}
{{< tdopen >}}
Dr. Keith Hoffmaster: Case Study: PK / PD
{{< tdclose >}}
{{< tdopen >}}
No readings for this session.
{{< tdclose >}}

{{< trclose >}}
{{< tropen >}}
{{< tdopen >}}
L22
{{< tdclose >}}
{{< tdopen >}}
Case Study: Sarilumab Phase III Clinical Result
{{< tdclose >}}
{{< tdopen >}}


Carroll, John. "[Regeneron, Sanofi Hit a Trio of Goals in First PhIII Test of Rheumatoid Arthritis Drug](http://www.fiercebiotech.com/story/regeneron-sanofi-hit-trio-goals-first-phiii-test-rheumatoid-arthritis-drug/2013-11-22)." _Fierce Biotech_, November 22, 2013.

Huet, Natalie (rep.) and Elizabeth Piper (ed.). "[Sanofi, Regeneron Arthritis Drug Meets Goals in Phase 3 Trial](http://www.reuters.com/article/2013/11/22/us-sanofi-regeneron-clinicaltrial-idUSBRE9AL06S20131122)." _Reuters_, November 22, 2013.

Bennett, Simeon. "[Sanofi Rheumatoid Arthritis Drug Cuts Pain, Damage in Study](http://www.bloomberg.com/news/2013-11-22/sanofi-rheumatoid-arthritis-drug-reduces-pain-damage-in-study.html)." _Bloomberg_, November 22, 2013.


{{< tdclose >}}

{{< trclose >}}
{{< tropen >}}
{{< tdopen >}}
R11
{{< tdclose >}}
{{< tdopen >}}
Prof. Doug Lauffenburger: Systems Pharmacology
{{< tdclose >}}
{{< tdopen >}}
No readings for this session.
{{< tdclose >}}

{{< trclose >}}
{{< tropen >}}
{{< tdopen >}}
L23
{{< tdclose >}}
{{< tdopen >}}
Dr. Tess Schmalbach, Schmalbach LLC: The Clinical Size of Drug Development
{{< tdclose >}}
{{< tdopen >}}
\[Golan\] Chapters 50 and 51
{{< tdclose >}}

{{< trclose >}}

{{< tableclose >}}